NBY - NovaBay Pharmaceuticals, Inc.

NYSE American - Nasdaq Real Time Price. Currency in USD

2.02

+0.12 (+5.86%)

At close: 3:13PM EDT

Stock chart is not supported by your current browser

Previous Close	2.03
Open	2.10
Bid	0.00 x 900
Ask	0.00 x 1800
Day's Range	2.02 - 2.15
52 Week Range	2.00 - 4.80
Volume	17,601
Avg. Volume	11,537

Market Cap	34.52M
Beta	-0.67
PE Ratio (TTM)	N/A
EPS (TTM)	-0.37
Earnings Date	Nov 8, 2017 - Nov 13, 2017
Forward Dividend & Yield	N/A (N/A)
Ex-Dividend Date	N/A
1y Target Est	3.69

Trade prices are not sourced from all markets

All

News

Press Releases

Business Wire10 days ago
NovaBay Pharmaceuticals Reports Second Quarter 2018 Financial Results
Conference call begins today at 4:30 p.m. Eastern time
ACCESSWIRE10 days ago
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 7, 2018 / NovaBay Pharmaceuticals, Inc. (NYSE MKT: NBY ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern ...
Business Wire17 days ago
NovaBay Pharmaceuticals to Hold Second Quarter 2018 Conference Call on August 7, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces that it will report second quarter 2018 financial results after market close on Tuesday, August 7.
Business Wirelast month
NovaBay Pharmaceuticals Expands Sales Organization to Re-energize Growth
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces it has completed the most recent planned expansion of its salesforce by hiring of 7 sales representatives. The Company now has a commercial salesforce of 45 representatives as the Company pursues profitable growth. “We are very encouraged by the high quality of our new hires, all of whom have significant experience in promoting prescription ophthalmic products,” said Mark M. Sieczkarek, NovaBay’s Chairman, President and CEO.
Business Wire3 months ago
NovaBay Pharmaceuticals Reports First Quarter 2018 Financial Results
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three months ended March 31, 2018 and provides a business update.
Business Wire3 months ago
NovaBay Pharmaceuticals to Hold First Quarter 2018 Conference Call on May 10, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report first quarter 2018 financial results after market close on Thursday, May 10.
Business Wire5 months ago
NovaBay Pharmaceuticals Reports 2017 Fourth Quarter and Full Year Financial Results
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, reports financial results for the three and 12 months ended December 31, 2017 and provides a business update.
ACCESSWIRE5 months ago
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / March 20, 2018 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 20, 2018, at 4:30 ...
Benzinga5 months ago
NovaBay Pharmaceuticals Q4 Earnings Outlook
On Tuesday, NovaBay Pharmaceuticals (NYSE: NBY ) will release its latest earnings report. Decipher the announcement with Benzinga's help. Earnings and Revenue NovaBay Pharmaceuticals EPS will likely be ...
Reuters6 months ago
BRIEF-Jinzi Ham's Unit Scraps Plan To Invest In Novabay Pharma, To Boost Asset Management Subsidiary's Capital
(Correct second bullet to boost unit’s capital by 90 mln yuan, instead of 90-100 mln yuan) March 1 (Reuters) - Jinzi Ham Co Ltd : * SAYS UNIT SCRAPS PLAN TO INVEST IN NOVABAY PHARMACEUTICALS INC * SAYS ...
Business Wire6 months ago
NovaBay Pharmaceuticals to Hold 2017 Fourth Quarter and Full Year Conference Call on March 20, 2018
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report 2017 fourth quarter and full year financial results after market close on Tuesday, March 20.
Business Wire6 months ago
NovaBay Pharmaceuticals Completes $6.0 Million Private Placement
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focused on commercializing Avenova®, a prescription product for the domestic eye care market, announces the completion of a private placement of 1.7 million shares of common stock to OP Financial Investments Limited for gross proceeds of $5,984,000.
Business Wire7 months ago
NovaBay Pharmaceuticals Announces Preliminary Sales for 2017 Fourth Quarter and Full Year
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® lid and lash hygiene for the domestic eye care market, announces that sales for the fourth quarter of 2017 are expected to slightly exceed $6 million, an increase of more than 49% over the prior-year period.
Business Wire8 months ago
NovaBay Pharmaceuticals Receives Stockholder Approval for Proposed $10.32 Million Financing Agreement
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for the domestic eye care market, announces stockholder approval to issue NovaBay common stock as part of a $10.32 million financing agreement with Ch-gemstone Capital Co., Ltd.
Business Wire8 months ago
NovaBay Pharmaceuticals Regains Compliance with NYSE American Continued Listing Standards
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova lid and lash hygiene for the domestic eye care market, announces that it has regained compliance with NYSE American continued listing standards.
Capital Cube8 months ago
ETFs with exposure to NovaBay Pharmaceuticals, Inc. : December 19, 2017
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to NovaBay Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to NBY-US. Comparing the performance and risk of NovaBay Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Business Wire8 months ago
NovaBay Pharmaceuticals Names Lewis J. Stuart Chief Commercial Officer
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, announces the appointment of Lewis J.
Capital Cube9 months ago
NovaBay Pharmaceuticals, Inc. :NBY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
Categories: Yahoo FinanceGet free summary analysis NovaBay Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of NovaBay Pharmaceuticals, Inc. – Johnson & Johnson, Tetraphase Pharmaceuticals, Inc., NanoViricides, Inc. and Sonoma Pharmaceuticals, Inc. (JNJ-US, TTPH-US, NNVC-US and SNOA-US) that have also reported for this period. ... Read more (Read more...)
Business Wire9 months ago
NovaBay Pharmaceuticals Reports Third Quarter 2017 Financial Results
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing prescription Avenova® for lid and lash hygiene in the domestic eye care market, reports financial results for the three and ninth months ended September 30, 2017 and provides a business update.
ACCESSWIRE9 months ago
NovaBay Pharmaceuticals, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / November 14, 2017 / NovaBay Pharmaceuticals, Inc. (NYSE American: NBY ) will be discussing their earnings results in their Q3 Earnings Call to be held on Tuesday, November 14, ...
Reuters9 months ago
BRIEF-Jinzi Ham's unit to invest in Novabay Pharma and become its biggest shareholder
Nov 14 (Reuters) - Jinzi Ham Co Ltd * Says unit signs agreement to buy shares in U.S. Novabay Pharmaceuticals Inc for a combined $27.06 million * Says unit will hold 37.14 percent stake in Novabay Pharmaceuticals ...
Business Wire9 months ago
NovaBay Pharmaceuticals to Hold Third Quarter 2017 Conference Call on November 14
NovaBay® Pharmaceuticals, Inc. , a biopharmaceutical company focusing on commercializing its prescription Avenova® lid and lash hygiene product for the domestic eye care market, announces that it will report third quarter 2017 financial results after market close on Tuesday, November 14.
ACCESSWIRE11 months ago
Dry Eye Advances from NovaBay and Johnson & Johnson Vision's TearScience
CEOCFO Magazine Reports on a Recent Roundtable of Top Eye Doctors, Who Highlighted Remarkable Advances in the Treatment of Dry Eye SAN DIEGO, CA / ACCESSWIRE / September 26, 2017 / CEOCFO Magazine , an ...
Business Wire11 months ago
NovaBay Pharmaceuticals Receives Notification of Noncompliance with Additional NYSE American Continued Listing Standards
NovaBay® Pharmaceuticals, Inc. announces receipt of a letter from NYSE American LLC on September 14, 2017 stating that it is not in compliance with the continued listing standard set forth in Section 1003 of the NYSE American Company Guide requiring stockholders’ equity of $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most ...